CGC · Canopy Growth Corporation · Stock research

Current Thesis

The federal rescheduling binary that gives CGC its beta has come and gone without a verdict. The DEA's expedited hearing on moving adult-use marijuana from Schedule I to Schedule III closed 2026-07-15 after 17 days; on 2026-07-16 Chief ALJ Derek Julius set post-hearing briefs due 2026-08-17, and no timeline was announced for his recommendation or the administrator's final rule (Cannabis Legalization News; Gibson Dunn, 2026-07). The record actually leaned constructive — the DEA itself argued as proponent while seven designated opponents cross-examined the government's own pain doctors — but a favorable evidentiary stance with no decision date, and a final rule near-certain to be litigated into 2027, is not a tradeable momentum event. Shares closed $0.8886 on 2026-07-24, pinned ~5% above the $0.8435 52-week low. Canopy is a Canadian LP that collects no direct 280E relief from a US adult-use reschedule. The event-option is bleeding out and price confirms it.

Bullish and bearish views on Canopy Growth Corporation

The model's bull view on Canopy Growth Corporation (CGC), in brief: Evidentiary record leaned pro-reschedule: across the 2026-06-29 → 2026-07-15 hearing the DEA acted as the Schedule III proponent, and its witnesses spent two weeks presenting marijuana's medical value and relative safety while prohibitionists held the cross (Cannabis… The bear view: The catalyst produced no decision: 2026-07-15 ended the evidentiary phase only. Both cases follow in full.

Bull Case

• Evidentiary record leaned pro-reschedule: across the 2026-06-29 → 2026-07-15 hearing the DEA acted as the Schedule III proponent, and its witnesses spent two weeks presenting marijuana's medical value and relative safety while prohibitionists held the cross (Cannabis Legalization News, 2026-07). If the ALJ recommendation tracks that record, the whole cannabis basket re-rates and a sub-$1 float gaps.
• Direction of travel is set: the DOJ/DEA order effective 2026-04-28 already moved FDA-approved marijuana drug products and state-licensed medical marijuana to Schedule III — the first Schedule I exit in five decades (Federal Register, 2026-04-28). Only the adult-use leg is unresolved.
• Balance sheet repaired: FY2026 (reported 2026-06-15) closed in a net cash position of +$131.3M, a ~$304M swing from net debt a year earlier after the January 2026 recapitalization; free cash outflow was cut to $69.1M and management guided to positive adjusted EBITDA during FY2027.
• Top line re-growing: Q4 FY2026 net revenue $71.2M, +10% YoY, with Canada medical +27% and international cannabis +68% YoY; the MTL Cannabis deal (closed 2026-03-16) made Canopy the largest Canadian medical cannabis company by revenue.
• Medical-value data keeps accruing: a study covered 2026-07-20 (Marijuana Moment) reported THC/CBD reduced agitation in 9 of 10 dementia patients — incremental support for the medical thesis underpinning the reschedule, though not a stock catalyst.

Bear Case

• The catalyst produced no decision: 2026-07-15 ended the evidentiary phase only. Briefs land 2026-08-17, then an undated ALJ recommendation, then a DEA final rule that will "likely face federal appellate challenge, potentially extending the process into 2027" (Cannabis Legalization News, 2026-07). Most of the float positioned for a July re-rate got a paper trail instead.
• Wrong vehicle: 280E tax relief from adult-use rescheduling accrues to US plant-touching MSOs — Trulieve (TCNNF), Green Thumb (GTBIF), Curaleaf (CURLF) — not a Canadian LP whose US exposure runs indirectly through Canopy USA. A positive rule helps the MSOs' cash flow directly and CGC's only by sentiment.
• Dilution caps every rally: shares outstanding reached 422.15M on 2026-07-24 (stockanalysis.com), up from ~378M reported in June and +163% YoY earlier, via ATM issuance and stock-funded M&A. Even constructive headlines get absorbed by supply.
• Not a squeeze: short interest sits near ~6% of float (MarketBeat, May 2026) — thin fuel for a violent short-cover leg, so the name behaves as a pure policy option rather than a squeeze vehicle.
• Tape is making lows, not bases: the $0.92–$1.06 band held in early July has broken; $0.8886 on 2026-07-24 sits just above the $0.8435 low with the 8-analyst consensus a lukewarm Hold at a $1.23 target.

Setup & Price Structure

Price is decelerating into the low end of its range. The stock closed $0.8886 on 2026-07-24 (-1.82% on the day, market cap $380.70M), roughly 5% above the $0.8435 52-week low and ~63% below the $2.38 high. The early-July legalization-optimism pop to the $0.92–$1.06 band has rolled over, and the structure is a fresh-low retest rather than a higher-low base. There is no clean momentum entry here: an accelerating narrative pulls price up and away from support, and CGC is doing the opposite — grinding toward its low as the catalyst timeline stretches out. Any constructive read requires the stock to first build a higher low and reclaim the $1.06 shelf on volume, which has not happened. For a sub-$1 policy proxy, position sizing stays tight regardless — the name moves violently on any rescheduling headline in either direction.

Catalyst Calendar (next 30 days)

• 2026-08-17 (confirmed) — DEA post-hearing briefs due (max 50 pages each), per Chief ALJ Julius's 2026-07-16 order. Marks the end of the written record; the ALJ recommendation follows on an unannounced schedule after this.
• No dated rescheduling decision in the window — the ALJ recommendation and the DEA administrator's final rule have no announced timeline; realistic resolution is H2 2026 at the earliest, with appellate risk into 2027.

Elapsed catalysts

• 2026-08-07 (confirmed) — Q1 FY2027 results (quarter ended 2026-06-30) before market open, webcast 10:00 AM ET with CEO Luc Mongeau and CFO Tom Stewart (StockTitan / Canopy Growth IR). This is a binary print for a thesis that is not earnings-driven; given the dilution and cash-burn backdrop the skew is negative. Avoid fresh entries inside 3 trading days of the print. (passed 2d ago)

What Would Change Our Mind

A move back to a constructive stance needs the narrative to re-accelerate with a real clock on it: a dated ALJ recommendation favoring Schedule III landing in H2 2026 rather than slipping to 2027, and US MSOs (MSOS ETF, TCNNF/GTBIF/CURLF) breaking out in cluster to confirm the theme is live again. On the tape, a reclaim of the $1.06 shelf off a higher low above $0.84 on expanding volume would turn the structure from fresh-low retest to base. A Q1 FY2027 print on 2026-08-07 that shows sustained double-digit revenue growth and pulls forward the positive-adjusted-EBITDA guide would harden the fundamental floor. Conversely, a daily close below $0.84 prints a fresh 52-week low and confirms the event-option has bled out; further ATM dilution above 422M shares, or the recommendation timeline sliding openly into 2027, deepens the bear read.

Correlation Notes

CGC trades as a high-beta, sub-$1 proxy on US cannabis policy headlines despite being Canadian, so it correlates tightly with the MSOS ETF and the US MSO complex (TCNNF, GTBIF, CURLF) and with Canadian peers Tilray (TLRY) and Aurora (ACB). On a favorable reschedule the MSOs capture the 280E cash-flow benefit directly and are the cleaner conviction vehicle; CGC captures sentiment beta only. Correlation to the broad market is low — the name is driven by DEA/DOJ policy flow, legalization retail sentiment, and its own dilution cadence rather than macro. Expect violent, headline-driven co-movement across the cannabis basket in both directions around any ALJ or administrator news after the 2026-08-17 brief deadline.